Reported by 1 source

The short version

  • A new personalized mRNA vaccine called intismeran helped prevent melanoma from returning when used alongside existing immunotherapy in a large clinical trial.
  • The treatment is tailored to each patient by sequencing tumor cells to identify unique mutations, training the immune system to target specific cancer markers.
  • While detailed data has not yet been released, experts view the results as a significant step toward broader applications for other types of cancer.

Moderna and Merck have announced positive results from a late-stage clinical trial involving a personalized cancer vaccine designed to prevent the recurrence of melanoma. The drug, known as intismeran, was administered in combination with pembrolizumab, an established immunotherapy medication also developed by the two companies. According to the manufacturers, patients who received both treatments experienced longer periods without their cancer returning or spreading compared to those who received only the standard immunotherapy and a placebo.

Intismeran represents a distinct approach to oncology, functioning not as a preventive measure against initial infection but as a therapeutic tool for patients who have already undergone surgery for advanced melanoma. The vaccine utilizes messenger RNA technology, similar to that used in recent vaccines for respiratory viruses, but targets cancer-specific proteins rather than viral antigens. This method aims to train the patient’s immune system to recognize and attack residual cancer cells that may remain after surgical removal.

News Journal

The creation of each vaccine dose is a highly individualized process that takes approximately six weeks. Researchers begin by sampling the patient’s tumor tissue and genetically sequencing the cells to identify unique mutations. These mutations cause tumor cells to produce specific proteins called neoantigens on their surface. The personalized vaccine is then engineered to help the immune system detect these neoantigens, effectively marking the cancer cells for destruction.

The trial involved 1,137 patients whose advanced melanoma had been surgically removed but was considered at high risk for returning. All participants received pembrolizumab, while roughly half were also given intismeran and the other half received a placebo. The study was double-blind, meaning neither the patients nor their physicians knew which treatment each individual received. This design helps ensure that the observed benefits are attributable to the vaccine rather than psychological factors or observer bias.

While Moderna and Merck have not released detailed statistical data from this specific trial, they described the outcomes as clinically meaningful. The companies plan to present the full findings at an upcoming international medical conference and submit them to regulatory authorities for review. These results follow earlier mid-stage trials that indicated a 49 percent reduction in the risk of melanoma recurrence or spread after five years when the vaccine was combined with pembrolizumab.

Melanoma remains the deadliest form of skin cancer, accounting for thousands of deaths annually in the United States. While early detection often leads to successful treatment, advanced cases that have spread deeper into the skin or other organs are significantly more difficult to manage. The ability to delay recurrence could therefore have substantial implications for patient survival rates and quality of life.

Independent experts who were not involved in the trial have responded cautiously but optimistically to the announcement. Specialists note that the results align with findings from smaller studies conducted in recent years, suggesting that personalized mRNA vaccines may indeed become a standard component of cancer therapy. The technology demonstrates that treatments once considered theoretical are now viable options for delaying disease progression.

Although this trial focused exclusively on melanoma, researchers believe the underlying approach could be adapted for other types of cancer. Personalized mRNA vaccines are currently in development for pancreatic, stomach, kidney, bladder, colon, and lung cancers. If successful, this model could also extend to rare conditions driven by specific genetic mutations, broadening the scope of precision medicine.

The next steps involve regulatory review and potential approval for wider clinical use. As more data becomes available from this and other ongoing studies, the medical community will assess the long-term efficacy and safety of personalized neoantigen therapies. For now, the announcement signals a growing confidence in the ability to tailor cancer treatments to individual genetic profiles.

Sources behind this briefing

Go to the original reporting